Atea Pharmaceuticals GAAP EPS of -$0.34 beats by $0.15
- Atea Pharmaceuticals press release (NASDAQ:AVIR): Q2 GAAP EPS of -$0.34 beats by $0.15.
Cash, Cash Equivalents and Marketable Securities: $608.1 million at June 30, 2023 compared to $646.7 million at December 31, 2022.